Format

Send to

Choose Destination
Vaccine. 2008 Aug 18;26(35):4420-4. doi: 10.1016/j.vaccine.2008.05.090. Epub 2008 Jun 25.

The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers.

Author information

1
Center for Infectious Disease and Vaccine Research, University of Massachusetts Medical School, Worcester, MA, USA. jsk07@health.state.ny.us

Abstract

This report describes the safety observations following administration of a polyvalent DNA prime-protein boost HIV-1 vaccine formulated with adjuvant QS21. Local injection site reactions were the most common (65% of subjects), and included type IV delayed-type hypersensitivity (DTH) reactions at prior DNA inoculation sites in 12 of 28 (43%) subjects following protein vaccination. Systemic reactions revealed two cases of vasculitis temporally related to inoculation with recombinant Env protein+QS21 adjuvant. Questions remain regarding the cause of the vasculitis, but the unique DTH observation may have contributed to the high level of immune responses previously reported for this vaccine.

PMID:
18588934
PMCID:
PMC2571083
DOI:
10.1016/j.vaccine.2008.05.090
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center